Last updated: February 4, 2026
Market Overview
Sacubitril and valsartan, branded as Entresto (by Novartis), Target heart failure treatment. Approved by FDA in July 2015, it received wider global approval within subsequent years. As a combination of neprilysin inhibitor sacubitril and angiotensin receptor blocker valsartan, this drug addresses heart failure with reduced ejection fraction (HFrEF).
Market Size and Growth
The global heart failure drug market reached approximately $9.2 billion in 2022. Sacubitril/valsartan accounted for roughly 30% of this market, implying sales around $2.76 billion. Compound annual growth rate (CAGR) from 2015 through 2022 averaged approximately 18%.
Market forecasts project continued expansion. By 2027, the HFrEF market could surpass $15 billion globally, driven by increased adoption, expanding indications, and broader geographic penetration. The growth rate is expected to remain robust, averaging 12–15% annually.
Competitive Landscape
Primary competitors include ACE inhibitors (enalapril, lisinopril) and other ARBs (losartan, valsartan alone). The entry of sacubitril/valsartan displaced many traditional therapies due to superior outcomes observed in pivotal trials like PARADIGM-HF.
Key players:
- Novartis: Dominates the market with Entresto, holding approximately 70% share in 2022.
- Mitsubishi Tanabe Pharma: Marketed canada's Entresto equivalent.
- Others: Generics of baseline ARBs available in various markets.
Novartis’s patents protected Entresto until 2031, though some formulation patents have faced challenges, opening avenues for generic entry.
Patent and Regulatory Environment
Entresto's U.S. patent estate includes patents expiring in 2031, with some pediatric exclusivities extending to 2036. Generic manufacturers have shown interest, pending patent challenges. Globally, patent statuses vary, with extensions and litigation influencing timing.
Regulatory pathways outside the U.S. involve European Medicines Agency (EMA) and other agencies approving similar formulations, often under different brand names.
Access and Adoption Trends
In the U.S., prescription adoption increased steadily, with around 50–60% of eligible heart failure patients receiving sacubitril/valsartan by 2022. Cost remains a barrier, limiting use in lower-income regions despite favorable reimbursement policies in certain countries.
In Europe and Japan, adoption rates lag slightly owing to reimbursement delays and regional prescribing guidelines. In emerging markets, access remains limited, but growth prospects exist with price reductions and local manufacturing.
Financial Trajectory
Revenue growth for sacubitril/valsartan follows patient population expansion and increased provider familiarity. The launch of generic versions, absent patent protections, could lower prices by 50–70%, causing revenue declines unless offset by volume growth or new indications.
Research into expanded uses involves trials for heart failure with preserved ejection fraction (HFpEF), hypertension, and renal protection. Successful extension of indications could boost market potential by 20–25% over current projections.
Key Risks and Opportunities
Risks:
- Patent expiry leading to generic competition.
- Pricing pressures reducing profit margins.
- Slower-than-expected adoption in certain regions.
Opportunities:
- New clinical data supporting broader indications.
- Higher penetration in underserved markets.
- Combination therapies targeting comorbid conditions like hypertension and kidney disease.
Summary
Sacubitril/valsartan's market is characterized by rapid growth, driven by clinical superiority over conventional therapies and expanding global healthcare infrastructure. Patent protections provide revenue stability until 2031, but upcoming patent challenges and patent expirations pose risks. Industry players are positioning for potential generic entry, balancing innovation with regulatory navigation.
Key Takeaways
- Sacubitril/valsartan achieved significant market share in heart failure treatment since 2015.
- The global market for heart failure drugs is projected to exceed $15 billion by 2027.
- Patent expiries beginning in 2031 could significantly impact revenues unless new indications are approved.
- Adoption varies globally, influenced by regulatory, reimbursement, and economic factors.
- Future growth hinges on clinical development, geographic expansion, and competitive pricing strategies.
FAQs
1. When will sacubitril/valsartan face generic competition? Patent protections extend until 2031 in the U.S., with some challenges potentially affecting this timeline. Patent expiry in other jurisdictions may vary.
2. Are there new indications for sacubitril/valsartan under clinical development? Yes. Trials investigate use in HFpEF, hypertension, and renal protection, which could expand the market.
3. How does sacubitril/valsartan compare cost-wise to ACE inhibitors? Currently, it is more expensive but has demonstrated superior outcomes. Post-patent expiry, prices may decrease substantially.
4. What regional differences affect market penetration? Reimbursement policies, regulatory approval procedures, and healthcare infrastructure influence adoption rates across different countries.
5. What are the primary drivers of future revenue growth? Clinical evidence supporting new indications, increased adoption in emerging markets, and volume growth in existing markets.
Sources
[1] IQVIA. "Global Heart Failure Market Data 2022."
[2] Novartis. "Entresto (Sacubitril/Valsartan) Patent and Regulatory Status."
[3] MarketWatch. "Heart Failure Drugs Market Forecast," 2022-2027.
[4] ClinicalTrials.gov. "Trials for Sacubitril-based Therapies."
[5] FDA. "Drug Approvals and Patent Expiry Schedule."
